Phase II study of interferon-α and all-trans retinoic acid in metastatic renal cell carcinoma

Journal of Immunotherapy

Volumn 21, Issue 1, 1998, Pages 62-64

  Escudier, Bernard ^a   Ravaud, Alain ^b   Berton, Dominique ^c   Chevreau, Christine ^d   Douillard, Jean Yves ^e   Dietrich, Yves Pierre ^a,f,g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g FNCLCC   (France)

Author keywords

All trans retinoic acid; Interferon ; Renal cell carcinoma, metastatic

Indexed keywords

ALPHA INTERFERON; RETINOIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; TRETINOIN;

EID: 0031973671     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199801000-00008     Document Type: Article

References (16)

1. Athanasiadis 1, Kies MS, Miller M, et al. Phase II study of alltrans-retinoic acid and α-interferon in patients with advanced nonsmall cell lung cancer. Clin Cancer Res 1995;1:973-9.
2. Bergerat JP, Herbrecht R, Dufour P, et al. Combination of recombinant interferon alpha 2a and vinblastine in advanced renal cell cancer. Cancer 1988;62:2320-4.
3. Escudier B, Douillard JY, Chevreau C, et al. Is it useful to switch to interleukin 2 or interferon when progressive disease occurs after a first treatment with one of these cytokines? Proc Am Soc Clin Oncol 1997;16:318a.
4. Escudier B, Ravaud A, Fabbro M, et al. High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study. J Immunother 1994;16:306-12.
5. Fossa SD, De Garis ST, Heier MS, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 1986;57:1700-4.
6. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-a. Eur J Cancer 1994;9:1310-4.
7. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha, and their combination in five human transformed cell lines. Cancer Lett 1991;57:223-7.
8. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
9. Motzer RJ, Schwartz L, Law TM, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-7.
10. Muss HB. Renal cell carcinoma. In: De Vita V, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer? Philadelphia: JB Lippincott, 1991:298-311.
11. Nanus DM, Bogenrieder T, Engelstein D, et al. Analysis of retinoid receptors (RAR) and retinoid inducedantiproliferative effects alone and in combination with interferon-alpha in human renal cancers: aberrant RAR alpha transcript in a retinoid resistant cell line. Proc Annu Meet Am Assoc Cancer Res 1994;35:A506.
12. Négrier S, Escudier B, Lasset C, et al. The FNCLCC CRECY trial: interleukin 2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 1996;15:248.
13. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
14. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
15. Toma S, Monteghirfo S, Tasso P, et al. Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines. Cancer Lett 1994;82:209-16.
16. West WH, Tauer KW, Yanelli JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl Med 1987;316:898-905.